1. Home
  2. SGRY vs SUPN Comparison

SGRY vs SUPN Comparison

Compare SGRY & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Surgery Partners Inc.

SGRY

Surgery Partners Inc.

N/A

Current Price

$26.81

Market Cap

3.0B

Sector

Health Care

ML Signal

N/A

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

N/A

Current Price

$29.59

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SGRY
SUPN
Founded
2004
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.5B
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
SGRY
SUPN
Price
$26.81
$29.59
Analyst Decision
Hold
Strong Buy
Analyst Count
6
7
Target Price
$24.40
★ $54.14
AVG Volume (30 Days)
★ 7.0M
2.4M
Earning Date
11-09-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
54.14
★ 8100.00
EPS
N/A
★ 2.78
Revenue
$1,145,438,000.00
★ $1,239,000,000.00
Revenue This Year
N/A
$51.56
Revenue Next Year
N/A
$30.35
P/E Ratio
★ N/A
$10.65
Revenue Growth
N/A
★ 4.29
52 Week Low
$11.41
$25.92
52 Week High
$27.23
$59.68

Technical Indicators

Market Signals
Indicator
SGRY
SUPN
Relative Strength Index (RSI) 89.82 31.65
Support Level $13.25 $25.92
Resistance Level N/A $51.59
Average True Range (ATR) 0.28 2.00
MACD 0.31 -0.52
Stochastic Oscillator 90.62 19.96

Price Performance

Historical Comparison
SGRY
SUPN

About SGRY Surgery Partners Inc.

Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: